Rui Vision Secures RMB 50 Million Series A Funding Led by BlueRun Ventures to Advance Myopia Control AR/VR Medical Devices

VCBeat learned第一时间 that Shanghai MetaVision Health Technology announced the completion of a 50 million RMB A round of financing,This round of financing was led by BlueRun Ventures China, with co-investment from CICC Healthcare.The proceeds from this round of financing will be mainly used for the continuous R&D of myopia prevention and control products by MetaVision, expanding production scale to achieve mass production, and the expansion of the R&D team's expert lineup.

MetaVision, founded in 2017, has been deeply engaged in the field of myopia prevention and control for children and adolescents since its establishment. Under the leadership of Professor Ningli Wang (CPPCC National Committee member, Academician of the International Academy of Ophthalmology, former chairman of the Ophthalmology Branch of the Chinese Medical Association), the company's chief scientist and co-inventor of the distant image light screen, and Professor Yongtian Wang (CPPCC National Committee member, specially appointed professor at the School of Optoelectronics, Beijing Institute of Technology, and director of the Beijing Advanced Display and Mixed Reality Research Center), MetaVision has launched its core product: the distant image light screen for myopia prevention and control. MetaVision has entered into in-depth cooperation with Beijing Tongren Hospital and the National Ophthalmic Engineering Center, combining top medical expertise with cutting-edge optical technology to create a powerful tool for myopia prevention that transforms the reading habits of children and adolescents.

MetaVision's Far-View Optical Screen adopts three core technologies: simulated long-distance HD imaging, digital spectral structure, and digital defocus & blur stimulation. Integrated with AR free-form surface patented technology, it enables children to view magnified, high-definition images and customized digital learning and entertainment content on the screen through optical principles and technological empowerment. It fundamentally avoids transient myopia caused by prolonged near-eye use, reduces visual fatigue and spasm-induced myopia, and prevents the accumulation of transient myopia, thereby lowering the risk of myopia onset and progression. The Far-View Optical Screen fills a market gap in protecting the hyperopia reserve for teenagers and controlling the development of myopia in children and adolescents, making it an innovative high-tech medical device for myopia prevention and control.

MetaVision's far-field light screen has won various industry awards with its extraordinary strength. It was selected as one of the top ten advances in Chinese ophthalmology in 2021, awarded the "2021 Ophthalmic Science and Technology Progress Honor" by the Chinese Medical Equipment Association, and obtained a Class II medical device registration certificate in China. The product has been widely sold in China and has received unanimous praise from parents and children.

Mr. Yao Jun, founder of MetaVision, said"BlueRun Ventures China and Sinopharm Capital's participation will not only provide capital support but also leverage their industry resources in healthcare and innovative medical devices to help MetaVision attract more professional talent, increase R&D investment, and accelerate product industrialization. As the Chinese government places greater emphasis on myopia prevention and control for children and adolescents, along with the increasingly evident trend of high myopia rates and early diagnosis among Chinese youth, myopia prevention and control for children and adolescents will become an essential service for every household in the future."

Cao Wei, partner of BlueRun Ventures China, the leading investor, stated"In recent years, myopia among teenagers has become a social issue that cannot be ignored. We are glad to see that the MetaVision team has innovatively applied AR optical technology to the clinical optometry field and launched an original distant image light screen product. In the six months since its release, the product has received numerous positive reviews from professional ophthalmologists and parents of children with myopia. Looking ahead, we expect the company to continue focusing on the underlying core technology platform, deepen its efforts in the field of myopia prevention and treatment, and launch more excellent products to bring hope to more families affected by myopia."

Mr. Yao Jun also stated"In the future, MetaVision will continue to leverage its leading optical technology capabilities and comprehensive myopia prevention and control solutions, continuously optimize its product portfolio led by the 'Far-Field Light Screen,' and further enhance the overall solution of 'hardware + software + services.' Collaborating with all sectors of society, it aims to connect families with hospitals, online with offline, and prevention with intervention. MetaVision is committed to promoting the standardization, convenience, precision, digitalization, and intelligent development of myopia prevention and control efforts, building a high-quality, high-standard, and high-level myopia prevention and control service system."

MetaVision will continue to promote the professional technical development of distant image light screens, accelerate their promotion and application in the field of optometry, and bring revolutionary changes to myopia prevention and control as well as eye-use scenarios for children and adolescents in China. The company will also continuously iterate and develop its product system, providing more innovative solutions and services for children and adolescents, supporting the implementation of policies such as China's "Comprehensive Plan for the Prevention and Control of Myopia in Children and Adolescents" and the "14th Five-Year National Eye Health Plan (2021-2025)," contributing to the realization of Healthy China.